CEL-SCI Corporation  

(Public, NYSEMKT:CVM)   Watch this stock  
Find more results for CVM
+0.050 (7.46%)
Jan 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.67 - 0.74
52 week 0.54 - 1.90
Open 0.67
Vol / Avg. 865,384.00/290,603.00
Mkt cap 60.36M
P/E     -
Div/yield     -
EPS -0.50
Shares 91.35M
Beta 0.83
Inst. own 8%
Feb 9, 2015
CEL-SCI Corp at Biotechnology Industry Organization CEO & Investor Conference - 4:00PM EST - Add to calendar
Jan 12, 2015
CEL-SCI Corp at EBD Biotech Showcase
Nov 3, 2014
September 2014 CEL-SCI Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -10648.47% -10364.83%
Operating margin -12550.93% -10443.56%
EBITD margin - -10290.47%
Return on average assets -130.51% -182.02%
Return on average equity -227.36% -332.30%
Employees 43 -
CDP Score - -


Suite 802, 8229 Boone Boulevard
VIENNA, VA 22182
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CEL-SCI Corporation (CEL-SCI) is a research and development company focused on improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. The Company is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. Its investigational immunotherapy is Multikine (Leukocyte Interleukin, Injection). The Company also owns and is developing a pre-clinical technology called Ligand Epitope Antigen Presentation System (LEAPS). The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. The Company�s Multikine, is being developed for the treatment of cancer. LEAPS is designed to stimulate the human immune system to effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own.

Officers and directors

Maximilian de Clara President, Director
Age: 84
Bio & Compensation  - Reuters
Geert R. Kersten Esq. Chief Executive Officer, Treasurer, Director
Age: 55
Bio & Compensation  - Reuters
Patricia B. Prichep Senior Vice President - Operations, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John Cipriano Senior Vice President - Regulatory Affairs
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel H. Zimmerman Ph.D. Senior Vice President - Research, Cellular Immunology
Age: 73
Bio & Compensation  - Reuters
Eyal Talor Ph.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Alexander G. Esterhazy Independent Director
Age: 72
Bio & Compensation  - Reuters
C. Richard Kinsolving Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters
Peter R. Young Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters